Recurrent foetal loss is a significant clinical problem, occurring in 1-5% of
reproductive females. Inherited or acquired thrombophilia has been diagnosed
in 50-65% of women with history of unexplained foetal loss. The low molecular
weight heparin was applied in 24 women with inherited thrombophilia and
previous recurrent foetal loss and in 6 women with primary antiphospholipid
syndrome throughout their following pregnancies. The dose of low molecular
weight heparin for the majority of women was 35-75 u/kg. Women with primary
antiphospholipid syndrome received both low molecular weight heparin and
aspirin 50-100 mg daily. Implementation of thromboprophylaxis resulted in
successful pregnancy outcome in 29 out of 38 pregnancies, which represents a
significant improvement of pregnancy outcome in comparison to previous 81
pregnancy losses. The number of treated pregnancies in our study is small,
but the rate of successful pregnancy outcomes is high (76%), indicating that
low molecular weight heparin may be a promising approach to women with
thrombophilia and recurrent foetal loss.
Low-molecular-weight heparin and aspirin use in relation to pregnancy outcome in women with systemic lupus erythematosus and antiphospholipid syndrome: A cohort study
